Stereotactic body radiation therapy after radical prostatectomy: current status and future directions
Jennifer Le Guévelou(Centre Eugène Marquis), Paul Sargos, Juan Martin Magsanoc(St. Luke's Medical Center), Tamim Niazi(Jewish General Hospital), Felipe Couñago(Hospital La Luz), R. de Crevoisier(Centre Eugène Marquis), S. Supiot(Institut de Cancérologie de l'Ouest), Piet Ost(Ghent University Hospital), Matthieu Vermeille(Clinique de Genolier), Nicolas Magné(Institut Bergonié), Nicolas Benziane-Ouaritini(Institut Bergonié)
Cited by 6
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer
|JAMA Oncology|2020|189
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus
|Radiotherapy and Oncology|2022|98
Proton therapy for locally advanced breast cancer: A systematic review of the literature
|Cancer Treatment Reviews|2017|60